Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Malonic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 known ✓ | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 1/20 | 0.33 |
| ▸ | LDHA | P00338 | 1/20 | 0.82 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.82 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.43 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.43 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 5/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.40 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malonic Acid SCHEMBL22466327 | 1.00 | — | — | |
| Malonic Acid SCHEMBL2321038 | 0.95 | — | — | |
| Malonic Acid SCHEMBL4306981 | 0.95 | — | — | |
| Malonic Acid SCHEMBL333874 | 0.95 | — | — | |
| Malonic Acid SCHEMBL11714473 | 0.91 | LDHA (0.82) | LDHASRRLMNAEGLN1ALKBH5 | |
| Malonic Acid SCHEMBL2823867 | 0.91 | — | — | |
| Malonic Acid SCHEMBL4620519 | 0.91 | — | — | |
| Malonic Acid SCHEMBL11137385 | 0.91 | — | — | |
| Malonic Acid SCHEMBL4365586 | 0.91 | LDHA (0.82) | LDHASRRLMNAEGLN1ALKBH5 | |
| Malonic Acid SCHEMBL15353415 | 0.91 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1816116-B3 | Chemical compositions and methods of making them | OMP INC (US) | 2016-08-03 | — | — | EP | disclosed |
| US-8952057-B2 | Compositions for anorectal use and methods for treating anorectal disorders | JR CHEM, LLC (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140248221-A1 | COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR CHEM, LLC (US) | 2014-09-04 | — | — | US | disclosed |
| US-20140228744-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR CHEM, LLC (US) | 2014-08-14 | — | — | US | disclosed |
| EP-1993569-B1 | ANTI-AGING TREATMENT USING COPPER AND ZINC COMPOSITIONS | OMP INC (US) | 2014-07-23 | — | — | EP | disclosed |
| EP-2718299-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR Chem, LLC (US) | 2014-04-16 | — | — | EP | disclosed |
| EP-1816116-B1 | Chemical compositions and methods of making them | JR CHEMICALS (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8505730-B2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | JR CHEM, LLC (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2012174076-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR CHEM, LLC (US) | 2012-12-20 | — | — | WO | disclosed |
| US-20120315224-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | JR CHEM, LLC | 2012-12-13 | — | — | US | disclosed |
| EP-2087880-A2 | Compositions, kits and regimens for the treatment of skin, especially décolletage | Jr Chem, LLC (US) | 2009-08-12 | — | — | EP | disclosed |
| US-20090176876-A1 | COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE | JR CHEM, LLC (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1993569-A1 | ANTI-AGING TREATMENT USING COPPER AND ZINC COMPOSITIONS | Jr Chem, LLC (US) | 2008-11-26 | — | — | EP | disclosed |
| WO-2008042197-A1 | METHOD OF WOUND/BURN HEALING USING COPPER-ZINC COMPOSITIONS | JR CHEM, LLC (US) | 2008-04-10 | — | — | WO | disclosed |
| US-20080081077-A1 | Method of wound/burn healing using copper-zinc compositions | LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT (CA) | 2008-04-03 | — | — | US | disclosed |
| US-20070203354-A1 | Chemical Compositions and Methods of Making Them | LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-30 | — | — | US | disclosed |
| US-20070191620-A1 | Chemical compositions and methods of making them | LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-16 | — | — | US | disclosed |
| WO-2007089267-A1 | ANTI-AGING TREATMENT USING COPPER AND ZINC COMPOSITIONS | JR CHEM, LLC (US) | 2007-08-09 | — | — | WO | disclosed |
| US-20070184017-A1 | Anti-aging treatment using copper and zinc compositions | LSSF II OFFSHORE INVESTMENTS, LP, AS ADMINISTRATIVE AGENT (CA) | 2007-08-09 | — | — | US | disclosed |
| EP-1816116-A1 | Chemical compositions and methods of making them | JR Chemicals (US) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228744-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | FABP6, ALPI, KRT18 | HDAC3 408/4885HDAC1 110/4885HDAC2 216/4885 |
| US-20120315224-A1 | APPLIANCES AND COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | FABP6, ALPI, KRT18 | HDAC3 408/4885HDAC1 110/4885HDAC2 216/4885 |
| US-20070203354-A1 | Chemical Compositions and Methods of Making Them | PARG, PCBP1, POLI | HDAC3 3571/4885HDAC1 3923/4885HDAC2 4371/4885 |
| US-20090176876-A1 | COMPOSITIONS, KITS AND REGIMENS FOR THE TREATMENT OF SKIN, ESPECIALLY DECOLLETAGE | RARG, RARA, RXRG | HDAC3 597/4885HDAC1 864/4885HDAC2 1602/4885 |
| US-20070191620-A1 | Chemical compositions and methods of making them | SOD1, CA6, SOD3 | HDAC3 3318/4885HDAC1 2933/4885HDAC2 4282/4885 |
| US-20140248221-A1 | COMPOSITIONS FOR ORAL USE AND METHODS FOR TREATING THE ORAL MUCOSA, LIPS, AND PERIORAL REGIONS | FABP2, MUC1, LPO | HDAC3 1675/4885HDAC1 1504/4885HDAC2 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.